FIELD: biotechnology; medicine.
SUBSTANCE: presented group of inventions relates to biotechnology and can be used in medicine. Invention discloses novel siRNAs capable of inhibiting the expression of the blood coagulation factor XI (FXI) gene in plasma, as well as conjugates based thereon.
EFFECT: invention can be used in preparing a drug used for treating or preventing thrombotic diseases and ischemic strokes.
18 cl, 8 ex, 17 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2819689C2 |
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD OF PRODUCTION AND USE | 2020 |
|
RU2816898C2 |
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN CELL | 2018 |
|
RU2822093C1 |
| CONJUGATES AND THEIR OBTAINING AND APPLICATION | 2018 |
|
RU2795400C2 |
| COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
| NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING IT, AS WELL AS METHOD FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2782211C2 |
| SILENSING OF TGF-BETA 1 AND Cox-2 USING siRNA DELIVERED IN A POLYPEPTIDE NANOPARTICLE, SINGLE AND IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF MALIGNANT NEOPLASM | 2019 |
|
RU2797510C2 |
| PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS OF TREATING TUMORS | 2019 |
|
RU2810906C2 |
| RNA MOLECULES CONTAINING NON-CANONICAL BASE PAIRS | 2019 |
|
RU2812710C2 |
